Lv61
1770 积分 2022-05-22 加入
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
5个月前
已完结
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
5个月前
已完结
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms
6个月前
已完结
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets
6个月前
已完结
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
7个月前
已完结
UncommonEGFRmutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)
8个月前
已关闭
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
8个月前
已完结
Biomarkers in Duchenne Muscular Dystrophy
9个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
11个月前
已完结
皖公网安备34019202002308
